search

Active clinical trials for "Skin Diseases"

Results 11-20 of 402

Evaluation of the Dermal Cooling System for Treatment of Common Skin Conditions

Skin Lesion

The purpose of this study is to evaluate whether the Dermal Cooling System can be used to elicit an improvement in the cosmetic appearance or physical symptoms of common skin conditions.

Recruiting18 enrollment criteria

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

Actinic KeratosisAcne/Rosacea5 more

This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment of skin disorders

Recruiting3 enrollment criteria

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial...

SclerodermaDiffuse10 more

The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

Recruiting27 enrollment criteria

OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women

Skin DiseasesSkin Disorder1 more

OneDoc Picopulse™ is a radiopulse technology beauty grade device invented for treating melasma.

Recruiting9 enrollment criteria

A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone...

Dermatologic Disease

One of the most frequent skin conditions is atopic dermatitis (AD), characterized by its pruritic inflammation effect. Where the prevalence of AD increased in the last three decades by two or three folds worldwide, especially in developed countries, AD is supposed to affect about 15% to 30% of children, and 2% to 10% of adults. This type of dermatitis is frequently linked to a family history of other atopic illnesses such as allergic rhinitis or asthma.

Recruiting2 enrollment criteria

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

Atopic DermatitisSkin Diseases

This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermatitis. The purpose of the study is to assess the effect of orismilast modified release in moderate-to-severe atopic dermatitis and assess the safety aspects of these 3 different doses. The patients will receive an oral treatment of either orismilast modified release tablets or placebo tablets 2 times a day for 16 weeks.

Recruiting11 enrollment criteria

Conservative Management of Cutaneous Abscess

Cutaneous Abscess

This is a single center non-blinded randomized trial of topical anesthetic cream to usual care (warm compresses and time) for superficial, non-perianal abscesses in children under 18 years of age. The primary outcome is time to spontaneous drainage. The secondary outcomes are return to emergency room/hospital/care provider and need for incision and drainage. Information on patient experience using standardized patient reported outcome measures for health-related quality of life will also be gathered. The findings of this study will provide more robust evidence of the benefit of this treatment including a potential reduction in cost and allow for more widespread dissemination.

Recruiting8 enrollment criteria

Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli

PruritusSkin Disorder

The objective of this double-blinded placebo-controlled cross-over study is to define the role of the over the counter agent, N-acetyl cysteine (NAC), in mitigating the development of pruritus (skin itching). The study is designed to have all subjects treated with a seven-day regimen of both NAC and placebo. NAC will be prescribed at a dose of 1,500 mg twice daily for seven days. Subjects will initially be randomly assigned (1:1) to either the NAC or placebo arm of the study, before crossing over to the opposite arm after completing a minimum of 30-day washout period. The study will encompass a period of approximately 11 weeks (about 2 and a half months).

Recruiting14 enrollment criteria

BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort

Atopic DermatitisSkin Diseases1 more

Atopic dermatitis (eczema) is a complicated skin condition. In fact, it represents many different underlying problems. These include abnormalities in the skin barrier, the immune system and the ability to handle different bacteria. Despite many recent gains in the understanding of eczema, a lot needs to be learned. There is little evidence to select between some of the older treatments that are available now. Even the newest targeted therapy does not clear most patients' skin. In order to improve the understanding of eczema, how to treat it now, and to enable discovery of new treatments, the investigators plan to enroll patients into a large study at three centres in Canada (University of Toronto, McGill University and University of British Columbia). The study is called the Canadian Atopic Dermatitis Cohort for Translational Immunology and Imaging (CACTI). In this study, the investigators will collect data on how severe participants' eczema is and what treatments they use. For participants who give permission, the investigators will collect blood and skin biopsy samples to study the mechanisms underlying their disease. The investigators will test to see which form of phototherapy (Broadband or Narrowband Ultraviolet B phototherapy) works best for eczema in a randomized clinical trial. The investigators will also use advanced imaging techniques to visualize the skin. This trial registry entry, including the description of the treatment arms and outcomes, refer to the nested BROadband vs Narrowband photoTherapy for Eczema clinical trial.

Recruiting8 enrollment criteria

Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for...

WrinkleFine Lines6 more

The goal of the Potenza device used in this study is to collect clinical data for dermatologic conditions in which electrocoagulation and hemostasis is a viable mechanism for means of improvement.

Recruiting34 enrollment criteria
123...41

Need Help? Contact our team!


We'll reach out to this number within 24 hrs